On November 22, Oncternal Therapeutics Announced That Nasdaq Plans To Delist Its Stock On December 3, Nasdaq Classified The Company As "Public Shell," Following Its Decision To Lay Off Employees And Explore Strategic Alternatives-Filing
On November 22, Oncternal Therapeutics Announced That Nasdaq Plans To Delist Its Stock On December 3, Nasdaq Classified The Company As "Public Shell," Following Its Decision To Lay Off Employees And Explore Strategic Alternatives-Filing
11月22日,oncternal therapeutics宣佈,納斯達克計劃於12月3日除牌其股票,納斯達克將該公司歸類爲「公開外殼」,此前該公司決定裁員並探索戰略性選擇-申報
Nasdaq will file a delisting notice with the SEC. Oncternal has stated it will not appeal the decision.
納斯達克將向美國證券交易委員會提交除名通知。Oncternal表示不會對該決定提出上訴。